“It was encouraging to see that cabozantinib resulted in significant delays in disease progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning medical ...

FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumors before the ... regimen for other forms of advanced NET, depending on tumor grade and different requirements for prior therapy.

"It was encouraging to see that cabozantinib resulted in significant delays in disease progression in the CABINET trial—regardless of primary tumor ... in Oncology for Neuroendocrine and Adrenal ...